Moreover, increased expression of BCL2 family members plays a role in the resistance of DLBCL to chemotherapy.7, 8 BCL6 was reported to be associated with a better prognosis, and patients with BCL6‐positive DLBCL experienced relatively favorable outcomes after treatment with the CHOP regimen.9 Although these biomarkers may predict the prognosis of DLBCL, few of them have been translated into clinical practice.10 This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.